https://openbell.ai/ 2026-11-09T17:16:47.001Z hourly 1.0 https://openbell.ai/support 2026-11-09T17:16:47.001Z monthly 0.7 https://openbell.ai/privacy 2026-11-09T17:16:47.001Z monthly 0.5 https://openbell.ai/terms 2026-11-09T17:16:47.001Z monthly 0.5 https://openbell.ai/feed.json 2026-11-09T17:16:47.001Z hourly 0.8 https://openbell.ai/news/AMCR:1794243708000 2026-11-09T17:01:48.000Z daily 0.9 https://cdn.brandfetch.io/AMCR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Amcor Reports Quarterly Financial Results and Updates Guidance Amcor reported September 2026-quarter sales of $6.13 billion, up 7%, while adjusted EPS fell to $0.95. Citing higher energy and distribution costs, the company lowered its semi-annual EPS forecast to $1.70–$1.80. Amcor recorded $60 million in quarterly synergies and reaffirmed targets of $130 million during the transition period and $650 million over three years; growth synergies added $170 million in annual sales. https://openbell.ai/news/CRSP:1794243703000 2026-11-09T17:01:43.000Z daily 0.9 https://cdn.brandfetch.io/CRSP/w/400/h/400?c=1idopYfmtR7ZKg8QMud CRISPR Therapeutics Presents Positive Phase 1b Clinical Data for CTX310 CRISPR Therapeutics reported Phase 1b results for CTX310, an investigational in vivo CRISPR/Cas9 therapy targeting ANGPTL3 in severe hypertriglyceridemia. At Day 30, a single treatment produced mean reductions from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides among participants whose median baseline triglyceride level exceeded 1,000 mg/dL. The data were presented at the 2026 American Heart Association Scientific Sessions, and the FDA has granted CTX310 RMAT designations for severe hypertriglyceridemia and elevated LDL-C. https://openbell.ai/news/OS:1794241959000 2026-11-09T16:32:39.000Z daily 0.9 https://cdn.brandfetch.io/OS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Officina Stellare Reports Strong Financial Growth and New Financing Officina Stellare reported sharp year-over-year growth in its order backlog and production value, alongside expanded margins and strong cash generation. It secured €75 million in financing to support growth, innovation, and recent M&A aimed at strengthening its technological capabilities in the aerospace and opto-mechanical sectors. The report did not provide specific growth rates, profit or revenue figures, or a stock-price impact. https://openbell.ai/news/CNCK:1794241943000 2026-11-09T16:32:23.000Z daily 0.9 https://cdn.brandfetch.io/CNCK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Coincheck Group Reports Financial Results for Second Quarter of Fiscal Year Ending March 31, 2027 Coincheck Group reported a 43% year-over-year revenue decline in the second quarter of fiscal 2027, citing weaker trading volumes, and swung to a net loss that included a ¥2.962 billion impairment related to its Aplo subsidiary. The company plans to wind down Aplo’s French brokerage operations and transfer its technology to 3iQ, targeting an SMA product launch in the first half of 2027. https://openbell.ai/news/ERAG:1794241929000 2026-11-09T16:32:09.000Z daily 0.9 https://cdn.brandfetch.io/ERAG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ernst Russ AG Raises Full-Year 2026 Forecast Ernst Russ AG raised its 2026 revenue forecast to EUR 159 million–EUR 164 million from EUR 150 million–EUR 160 million, and its EBIT outlook to EUR 63 million–EUR 70 million from EUR 55 million–EUR 65 million. The revision reflects a stronger US dollar, with the company now assuming an average rate of 1.12 USD/EUR for the rest of the year, versus 1.18 previously. The outlook also factors in fleet utilization of about 97% and existing charter agreements. https://openbell.ai/news/CFEB:1794241921000 2026-11-09T16:32:01.000Z daily 0.9 https://cdn.brandfetch.io/CFEB/w/400/h/400?c=1idopYfmtR7ZKg8QMud CFE Reports Strong Operational Performance and Profit Growth Compagnie d’Entreprises CFE reported year-over-year growth of 51% in operating income and 72% in net profit, despite revenue declining 2.6%. Strong performance in its Construction & Renovation and VMA segments offset challenges in Real Estate Development and MOBIX. The company also reported a robust order book and a strong net cash position. https://openbell.ai/news/NVCR:1794241900000 2026-11-09T16:31:40.000Z daily 0.9 https://cdn.brandfetch.io/NVCR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Novocure Receives FDA 'Not Approvable' Letter for Optune Mya Novocure received an FDA “Not Approvable” letter for its Optune Mya application to treat adults with brain metastases from non-small cell lung cancer after stereotactic radiation. The FDA cited uncertainty about the therapy’s degree of clinical benefit, but raised no concerns about device safety. Novocure is evaluating the feedback and plans to discuss possible approval paths with the FDA, including options that may not require additional clinical studies; approval is not guaranteed. https://openbell.ai/news/MNDY:1794240133000 2026-11-09T16:02:13.000Z daily 0.9 https://cdn.brandfetch.io/MNDY/w/400/h/400?c=1idopYfmtR7ZKg8QMud monday.com Reports Third Quarter 2026 Financial Results monday.com reported third-quarter 2026 revenue of $377.5 million, up 19.2% year over year and above analyst estimates, while adjusted EPS of $2.14 exceeded the $1.37 consensus. The company forecast fourth-quarter revenue of $380 million to $382 million, slightly below market expectations, and projected full-year 2026 revenue of $1.473 billion to $1.475 billion. Management said its shift toward becoming an AI-first company is creating near-term operational headwinds. https://openbell.ai/news/LLY:1794240107000 2026-11-09T16:01:47.000Z daily 0.9 https://cdn.brandfetch.io/LLY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Eli Lilly's Foundayo Meets Primary Endpoint in Phase 3 Sleep Apnea Trial Eli Lilly said Foundayo met the primary endpoint in a Phase 3 program, reducing obstructive sleep apnea breathing interruptions by approximately 44% among patients not using PAP therapy and nearly 28% among those using it. The company plans to submit the results to the FDA by the end of 2026 to seek approval for sleep apnea treatment. Lilly reported a safety profile consistent with earlier trials, with common adverse events including mild-to-moderate gastrointestinal effects. https://openbell.ai/news/MRK:1794240104000 2026-11-09T16:01:44.000Z daily 0.9 https://cdn.brandfetch.io/MRK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Eisai and Merck Receive Complete Response Letter for LENVIMA and KEYTRUDA Combination Merck and Eisai received a Complete Response Letter for their application seeking first-line approval of LENVIMA plus KEYTRUDA for patients with unresectable hepatocellular carcinoma. The letter means the application was not approved at this time; the companies are reviewing its contents and assessing next steps. The article reports no financial figures or stock-price impact.